Toxin HLX91-048 Based HER2 ADC And Its Unique Killing Mechanism



Figure 1. (A) Schematic diagram of HLX91-48 based HER2 ADCs. (B) Mechanistic representation of 3-(4-hydroxyphenyl)indoline-2-one derivative

In Vitro Characterization of HLX02-L1-P (HLX91-48 Based HER2 ADC)

A **B** **C** **D**




Figure 3. *In vitro* profiling of HLX02-L1-P binding affinity (A), internalization rates (B), and cytotoxic activity (C) of ADCs against $HER2^+$ BT474 cells. (D) Plasma stability of ADCs across preclinical species.

HLX91-048 Based HER2 ADCs Demonstrated Potent Antitumor Efficacy in BT474 Xenograft and DS-8201 Resistant NCI-N87R Models

A **B**




Figure 5. HER2 ADCs conjugated with HLX91-048-derived linker-payloads (L1-P & L2-P) demonstrate dose-dependent antitumor efficacy in $HER2^+$ BT474 model (A) and DS-8201-resistant NCI-N87R model (B). All ADCs were given intravenously once weekly.

HLX02-L1-P and HLX22-L2-P Were More Potent than DS-8201 Analog Against Treatment Resistant Patient-derived Organoids *in Vitro*



Figure 6. Cytotoxic efficacy of indicated ADCs against different PDOs assessed via CTG assay after 144h treatment